• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    PMGC Holdings Inc. Announces Over $711,000.00 in Sales Backlog at AGA Precision Systems LLC and Provides Corporate Update

    10/20/25 7:30:16 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ELAB alert in real time by email

    NEWPORT BEACH, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:ELAB) ("PMGC" or the "Company" or "we"), a diversified public holding company executing a targeted roll-up strategy in U.S.-based manufacturing, today announced that its operating subsidiary AGA Precision Systems LLC ("AGA") has reported a sales backlog of approximately over $711,000 in current orders logged into its Material Requirements Planning system, Sage100. AGA has also confirmed that it is actively bidding on additional Request for Quotations totaling over $700,000 from new customers. PMGC believes AGA's current backlog and pending orders reflect robust demand, underscoring AGA's growth momentum and the strong relationships it continues to build with both existing and new customers. PMGC also believes the backlog and pending orders strengthen AGA's position to expand its precision machining capabilities within the aerospace and defense sectors. The backlog and quotation figures referenced herein are internally prepared, unaudited, management estimates and remain subject to change.

    AGA's milestones during the current fiscal quarter included:

    Capability Expansion: AGA has expanded its manufacturing capabilities with the purchase of the following high performance machinery (delivery expected in Q4 2025):

    • YCM RX65 5 Axis
    • CMZ TA30Y High Performance Turning Center

    These machine's state-of-the-art Computer Numerical Control (CNC) systems are designed for true 5-axis simultaneous machining, reducing setups, improving accuracy, increasing throughput, and enabling the production of complex geometries in a single operation.

    The RX65, part of YCM's RF/RX series, is built on a rigid RAM-type structure for maximum stability, thermal control, and repeatability. This CNC platform allows operators to turn, mill, and drill complete parts in one setup producing more complex components faster and with higher precision. Engineered for power, rigidity, and accuracy, it is ideally suited for both heavy turning and fine milling, resulting in reduced setups, shortened lead times, and improved part quality.

    PMGC believes this machinery can expand AGA's machining capabilities across aerospace-grade materials, including inconel, titanium, steel, and aluminum. We expect these advanced technologies, following delivery, to enhance AGA's ability to meet the demanding technical requirements of its aerospace and defense customers, and improve production precision and accelerating delivery times.

    Team Growth & Community Impact: AGA now employs more than 15 full-time personnel across machining, quality assurance, and operations. The company anticipates doubling its production capacity over the next year, creating additional skilled manufacturing jobs within the California, Santa Ana community and contributing to local economic growth.

    Rebranding: AGA has completed a corporate rebranding, including a new logo and improved website at www.AGAPrecision.com.

    About AGA Precision Systems LLC

    AGA Precision Systems LLC is a specialized CNC machine shop focused on high-tolerance milling, turning, mold manufacturing, and machining of complex metals including titanium and Inconel. The company serves customers across the aerospace, defense, and industrial sectors, delivering precision components to demanding technical specifications.

    Founded over a decade ago, AGA has built a strong reputation for quality and reliability, having grown its business exclusively through referrals and repeat orders without a formal sales or marketing function. Its long-standing customer relationships and niche capabilities have supported consistent operating profitability from its base in California.

    About PMGC Holdings Inc.

    PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries. We are committed to exploring opportunities in multiple sectors to maximize growth and value. For more information, please visit https://www.pmgcholdings.com.

    Forward-Looking Statements

    Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "believes," "expects," "plans," "potential," "would" and "future" or similar expressions such as "look forward" are intended to identify forward-looking statements. Forward-looking statements are made as of the date of this press release and are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. Therefore, you should not rely on any of these forward-looking statements. These and other risks are described more fully in PMGC's filings with the United States Securities and Exchange Commission ("SEC"), including the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 28, 2025, and its other documents subsequently filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC's web site at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

    IR Contact:

    [email protected]



    Primary Logo

    Get the next $ELAB alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ELAB

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ELAB
    SEC Filings

    View All

    SEC Form S-1 filed by PMGC Holdings Inc.

    S-1 - PMGC Holdings Inc. (0001840563) (Filer)

    10/15/25 7:28:22 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form S-1/A filed by PMGC Holdings Inc.

    S-1/A - PMGC Holdings Inc. (0001840563) (Filer)

    10/15/25 4:47:32 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form PRE 14A filed by PMGC Holdings Inc.

    PRE 14A - PMGC Holdings Inc. (0001840563) (Filer)

    10/15/25 11:30:21 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO & CFO Bensler Graydon was granted 3,036,437 units of Series B Preferred Stock (SEC Form 4)

    4 - PMGC Holdings Inc. (0001840563) (Issuer)

    3/28/25 9:52:32 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: New insider Bensler Graydon claimed ownership of 983,120 shares (SEC Form 3)

    3/A - PMGC Holdings Inc. (0001840563) (Issuer)

    3/28/25 9:51:28 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Braeden Lichti was granted 3,336,437 units of Series B Preferred Stock (SEC Form 4)

    4 - PMGC Holdings Inc. (0001840563) (Issuer)

    3/28/25 9:47:45 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PMGC Holdings Inc. Announces Over $711,000.00 in Sales Backlog at AGA Precision Systems LLC and Provides Corporate Update

    NEWPORT BEACH, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:ELAB) ("PMGC" or the "Company" or "we"), a diversified public holding company executing a targeted roll-up strategy in U.S.-based manufacturing, today announced that its operating subsidiary AGA Precision Systems LLC ("AGA") has reported a sales backlog of approximately over $711,000 in current orders logged into its Material Requirements Planning system, Sage100. AGA has also confirmed that it is actively bidding on additional Request for Quotations totaling over $700,000 from new customers. PMGC believes AGA's current backlog and pending orders reflect robust demand, underscoring AGA's growth momentum and

    10/20/25 7:30:16 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Northstrive Biosciences Announces Completion of Phase II of AI Development Program with YuvaBio Using MitoNova™ Artificial Intelligence (AI) Platform to Develop Therapies for Obesity and Cardiometabolic Diseases

    Northstrive Biosciences and Yuva Biosciences previously announced the AI Development Program, a collaboration leveraging MitoNova™, YuvaBio's proprietary mitochondrial science-focused artificial intelligence platform, to discover and develop novel pharmaceutical treatments for obesity, type 2 diabetes and other cardiometabolic conditions.Phase II of this collaboration involved YuvaBio compiling a selection of small molecule candidates with the potential of promoting mitochondrial health to combat obesity and cardiac diseases. NEWPORT BEACH, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Northstrive Biosciences Inc. ("Northstrive"), a subsidiary of PMGC Holdings Inc. (NASDAQ:ELAB) (the "Compan

    9/4/25 9:54:12 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PMGC Holdings Inc. Announces Anticipated Reverse Stock Split

    NEWPORT BEACH, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:ELAB) ("PMGC" or the "Company") today announced that it will effect a 1-for-3.5 reverse stock split (the "Split") of its issued and outstanding and authorized common stock, par value $0.0001 per share ("Common Stock"). The marketplace effective date of the Split will be September 2, 2025 at 9:30 am EST. Key Details of the Reverse Stock Split: Conversion Ratio: Every 3.5 shares of issued and outstanding Common Stock will be consolidated into one share of Common Stock, and every 3.5 shares of authorized Common Stock will be consolidated into one share of Common Stock, each with no further action required fr

    8/28/25 10:30:00 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAB
    Leadership Updates

    Live Leadership Updates

    View All

    PMGC Holdings Inc. Expands Investment & M&A Efforts, Actively Seeking Acquisitions and Investments Through Strategic Sponsorship of TCA Venture Group

    NEWPORT BEACH, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (the "Company" or "PMGC," "our," or "we") (NASDAQ:ELAB), a diversified holding company, is proud to announce its annual sponsorship of TCA Venture Group's ("TCA") Orange County network for 2025. As a Southern California Network Sponsor, PMGC is actively pursuing investments and M&A opportunities to strengthen its portfolio while fostering local business growth and expanding its market presence. TCA Venture Group (formerly known as Tech Coast Angels) is one of the largest and most active angel investor networks in the United States. With a history spanning over 25 years, TCA has been instrumental in funding early-s

    2/27/25 8:00:00 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elevai Labs Inc. Subsidiary, Elevai Biosciences, Continues to Advance its Scientific Advisory Board with the Appointment of Orian Shirihai, MD, PhD

    Professor of Medicine at the University of California, Los Angeles (UCLA), where he serves as Director of the UCLA Metabolism Research Theme.Over 180 publications in the field of obesity & metabolism, along with multiple NIH-funded projects as Principal Investigator.Dr. Shirihai is a renowned researcher regularly invited as a keynote speaker at annual scientific conferences and has consulted for Johnson & Johnson, Bayer, AstraZeneca and Pfizer, among other healthcare companies. NEWPORT BEACH, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ:ELAB) ("Elevai" or the "Company"), a pioneering force in medical aesthetics, announced the appointment of Orian Shirihai, MD, PhD, t

    7/30/24 9:00:26 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elevai Labs Forms New Scientific Advisory Board for its Weight Loss Programs

    NEWPORT BEACH, Calif., June 14, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ:ELAB) ("Elevai" or the "Company"), a pioneering force in medical aesthetics, announced the formation of a new Scientific Advisory Board to support the advancement of EL-22, a first-in-class engineered probiotic approach, to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. "We are honored to be forming a Scientific Advisory Board with renowned members that possess deep and complementary knowledge in metabolic diseases, obesity, weight management, muscle preservation and physical function in addition to significant experience in clinical

    6/14/24 9:00:00 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    $ELAB
    Financials

    Live finance-specific insights

    View All

    SEC Form SC 13G filed by Elevai Labs Inc.

    SC 13G - Elevai Labs Inc. (0001840563) (Subject)

    11/14/24 5:53:26 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Elevai Labs Inc.

    SC 13G - Elevai Labs Inc. (0001840563) (Subject)

    10/2/24 4:01:03 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Elevai Labs Inc.

    SC 13G - Elevai Labs Inc. (0001840563) (Subject)

    10/1/24 4:01:02 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PMGC Holdings Inc. Completes Acquisition of CNC Machining Company - AGA Precision Systems LLC

    Adds $1.39 Million in Cash-Flow-Positive Revenue from a CNC Machining, Mold Manufacturing, and Specialty Metals Operation Serving the Aerospace, Defense, and Industrial Markets.Adds to PMGC's U.S. Manufacturing Revenue Through a Second Bolt-On Acquisition Under Its Roll-Up Strategy, Bringing Estimated Total Annualized Revenue to Over $2.25 Million. NEWPORT BEACH, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:ELAB) (the "Company," "PMGC" or "we"), a diversified public holding company, today announced that it has completed the acquisition of AGA Precision Systems LLC ("AGA"), a California-based CNC machining business that generated over $1.39 million in revenue in 2

    7/18/25 12:53:12 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PMGC Holdings Inc. Completes Acquisition of Custom IT Packaging Company Pacific Sun Packaging with Over $2,000,000 in Combined Revenue for Fiscal Years 2023 and 2024

    Serves over 300 Commercial Clients including Data Centers, Technology Manufacturers and Information Technology (IT) Service Providers.Adds cash flow positive revenue, enhances PMGC's exposure to U.S. semiconductor and artificial intelligence ("AI") infrastructure growth, and marks the launch of its strategic acquisition program targeting U.S. businesses. NEWPORT BEACH, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:ELAB) (the "Company," "PMGC," "we," or "us"), a diversified public holding company, today announced that it has completed the acquisition of Pacific Sun Packaging Inc. ("Pacific Sun") a specialized custom IT packaging company based in San Clemente, Califor

    7/10/25 8:30:00 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments

    Agreement adds two drug candidates to product pipeline consisting of (i) "EL-22", a clinical stage engineered probiotic expressing myostatin, and (ii) "EL-32", a preclinical engineered probiotic expressing dual myostatin & activin-A.Exclusive license covers global rights excluding South Korea.Clinical and preclinical data supports advancing EL-22, a novel investigational myostatin asset for the treatment of obesity for an investigational new drug "IND" application in 2025. EL-22 has demonstrated significant increase in body weight and restored muscle damage in preclinical mouse models, suggesting potential as a combination to glucagon-like peptide-1 "GLP-1" products to treat obesity. NEWPOR

    5/1/24 9:00:00 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care